New technologies and treatment methods are expanding men’s options. Here’s what you should know about your choices for ...

For men at the highest risk of prostate cancer as determined by a polygenic risk score, the percentage found to have clinically significant disease was higher than the percentage that would have been ...

Researchers at the Center for Computational Imaging and Personalized Diagnostics (CCIPD) at Case Western Reserve University have preliminarily validated an artificial intelligence (AI) tool to predict ...

PANAMA CITY, Fla. (WJHG/WECP) - Hope Regional Medical Center in Panama City is now using a powerful new diagnostic tool in the fight against Prostate Cancer. Doctors at the center have always used CT ...

Researchers at the Icahn School of Medicine at Mount Sinai have developed an advanced artificial intelligence (AI)-driven tool to improve the management and prognosis of prostate cancer. Recent ...

Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced that new data from the prospective, randomized integral biomarker BALANCE trial (NCT03371719) finds that the PAM50 ...

Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced today that the first prospective validation data for a molecular signature to predict hormone therapy benefit in men ...

In cases of clinical equipoise, the highest MMAI score quartile could guide selective treatment intensification among patients with high-risk nonmetastatic prostate cancer. An artificial ...

Artificial intelligence has danced around the fringes of prostate cancer for years, but in 2024, it got a profile-raising boost: An AI tool that could use biopsy images and clinical data to predict ...

In the modern era of advanced imaging and genomics testing, the digital rectal exam (DRE) is still an "important" and clinically relevant prognostic test for prostate cancer, conclude the authors of a ...

Veracyte (VCYT) announces randomized biomarker BALANCE trial finds that the PAM50 molecular signature predicts which patients with recurrent ...

A polygenic risk score was able to detect a high proportion of clinically significant prostate cancer. Cancer would not have been detected in 71.8% of patients with the use of PSA or MRI screening.